Angiotensin receptor blockers: RAAS blockade and renoprotection

Current Medical Research and Opinion

Volumn 24, Issue 5, 2008, Pages 1285-1293

  Ruilope, Luis M ^a,b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Angiotensin receptor blockers; Kidney disease; Renin angiotensin aldosterone system; Renoprotection

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN; METOPROLOL; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; VALSARTAN; VERAPAMIL;

BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; DIZZINESS; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; MEDLINE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEIOTROPY; PREDICTIVE VALIDITY; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CREATININE; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 44449164649     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X291921     Document Type: Review

References (61)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266
2. Johnson CA, Levey AS, Coresh J, et al. Clinical practice guidelines for chronic kidney disease in adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors. Am Fam Physician 2004;70:869-76
3. Bamgboye EL. Hemodialysis: management problems in developing countries, with Nigeria as a surrogate. Kidney Int 2003;83(Suppl):S93-5
4. Alebiosu CO, Ayodele OE. The global burden of chronic kidney disease and the way forward. Ethn Dis 2005;15:418-23
5. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69
6. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-95
7. Rossing P. Doubling of serum creatinine: is it sensitive and relevant? Nephrol Dial Transplant 1998;13:244-6
8. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985;28:830-8
9. Stevens LA, Levey AS. Measurement of kidney function. Med Clin North Am 2005;89:457-73
10. Verelli, M. Chronic renal failure. Available at: www.emedicine.com/med/ topic374.htm. [Last accessed 22 November 2007]
11. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305
12. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989;13(5 Suppl):I80-93
13. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001;12:218-25
14. Desai M, Stockbridge N, Temple R. Blood pressure as an example of a biomarker that functions as a surrogate. AAPS J 2006;8:E146-52
15. Ruilope LM, Zanchetti A, Julius S, et al. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J Hypertens 2007;25:1473-9
16. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6
17. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004;110:32-5
18. Rosario RF, Wesson DE. Primary hypertension and nephropathy. Curr Opin Nephrol Hypertens 2006;15:130-4
19. MacMahon S, Chalmers J. Blood pressure lowering and ACE inhibition for the avoidance of cardiac and cerebral events. Eur Heart J 2003;24:391-3
20. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
21. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
22. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004;116:263-72
23. Snively CS, Gutierrez C. Chronic kidney disease: prevention and treatment of common complications. Am Fam Physician 2004;70:1921-8
24. Perneger TV, Whelton PK, Klag MJ. History of hypertension in patients treated for end-stage renal disease. J Hypertens 1997;15:451-6
25. Perera GA. Hypertensive vascular disease; description and natural history. J Chronic Dis 1955;1:33-42
26. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001;104:1985-91
27. Ravera M, Re M, Deferrari L, Vettoretti S, Deferrari G. Importance of blood pressure control in chronic kidney disease. J Am Soc Nephrol 2006;17:S98-103
28. Taal MW. Slowing the progression of adult chronic kidney disease: therapeutic advances. Drugs 2004;64:2273-89
29. Jafary MH. Renoprotective benefits of renin-angiotensin system inhibition. What's the evidence? Pak J Med Sci 2002;18:311-5
30. Long DA, Price KL, Herrera-Acosta J, Johnson RJ. How does angiotensin II cause renal injury? Hypertension 2004;43:722-3
31. Epstein BJ. Elevations in serum creatinine concentration: concerning or reassuring? Pharmacotherapy 2004;24:697-702
32. Schmieder RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007;30:1351-16
33. Johnson DW, Usherwood T. Chronic kidney disease - management update. Aust Fam Physician 2005;34:915-23
34. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41:565-70
35. Ruilope LM. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers? Acta Diabetol 2005;42(Suppl 1):S33-41
36. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
37. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
38. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
39. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8
40. Haller H, Viberti GC, Mimran A, et al. Preventing micro-albuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006;24:403-8
41. Hollenberg NK, Parving H-H, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007;25:1921-6
42. Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005,68:1190-8
43. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51
44. Barnett A. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. J Am Soc Nephrol 2006;17(4 Suppl 2):S132-5
45. Strojek K, Grzeszczak W, Gorska J, et al. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001;12:602-5
46. Adler AI, Stevens RJ, Manley SE, et al; UKPDS Group. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32
47. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87
48. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285:2719-28
49. Feringa HH, Karagiannis SE, Chonchol M, et al. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or angiotensin-converting enzyme inhibitors. J Am Soc Nephrol 2007;18:1872-9
50. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24
51. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-33
52. Garcia-Donaire JA, Segura J, Ruilope LM. Clinical trials in nephrology: success or failure. Curr Opin Nephrol Hypertens 2007;16:59-63
53. Adler A, Stratton I, Shine B. Renoprotective effects of renin-angiotensin-system inhibitors. Lancet 2006;367:897-8
54. de Zeeuw D, Lewis EJ, Remuzzi G, et al. Renoprotective effects of renin-angiotensin-system inhibitors. Lancet 2006;367:899-900
55. Mann JF, Ritz E, Kunz R. Renoprotective effects of renin-angiotensin- system inhibitors. Lancet 2006;367:900-2
56. Parving HH, Rossing P. Renoprotective effects of renin-angiotensin-system inhibitors. Lancet 2006;367:898-9
57. Wogen J, Kreilick CA, Livornese RC, et al. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm 2003;9:424-9
58. Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001;59:2282-9
59. Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52-61
60. Codreanu I, Perico N, Remuzzi G. Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection? J Am Soc Nephrol 2005;16(Suppl 1):S34-8
61. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-93